



1AP7 Rec'd PCT/PTO 07 APR 2008

Patent Docket P5104R1



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Heidi Jenii Ackerly Wallweber Serial No.: 10/553,491 Filed: October 14, 2005 For: Compositions and Methods Relating to STOP-1	Group Art Unit: Not yet assigned Examiner: Not yet assigned Confirmation No: Not yet received CUSTOMER NO: 09157 CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 5, 2006  Bailey Lee
---	--

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); **or**
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, **or**
- before the mailing of the first Office action on the merits; **or**
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of

allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patent(s) and/or publication(s) is set forth on the attached revised Form PTO-1449. Copies of the items listed on the PTO-1449 form are supplied herewith. Copies of United States patents and United States patent application publications will not be supplied unless requested by the Office [37 CFR §1.98(a)(2)(ii)]. See Final Rule **1287 OG** (October 12, 2004). However, copies of any cited document will be provided in its entirety at the request of the Office.

☐ BLAST results enclosed:

The undersigned also wishes to bring to the attention of the Examiner BLAST results of computerized alignments of the against sequences contained in the nucleotide and protein databases. The BLAST results are provided in paper form and are identified as reference "BLAST Results A-1- A-()" (nucleotide) and "BLAST Results B-1 - B-()" (protein) on the PTO Form 1449. Applicant requests that these references also be considered and that the Form 1449 be initialed to indicate the Examiner's consideration of the references.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR § 1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR § 1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17 for this Information Disclosure Statement, or credit overpayment to Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: April 5, 2006

By: 

Elinor K. Shin

Reg. No. 43,117

Telephone No. (650) 225-3536



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P5104R1

Serial No.

10/553,491

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Heidi Jenii Ackerly Wallweber

Filing Date

14 Oct 2005

Group

Not yet assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	2002/0161211 A1	31.10.02	Lindner et al.			
	2	2005/0147602 A1	07.07.05	Lindner			
	3	5,821,337	13.10.98	Carter et al.			
	4	6,476,195 B1	05.11.02	Komatsoulis et al.			
	5	6,680,197 B2	20.01.04	Jiang et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	6	1179540 A1	13.02.02	EP			
	7	WO 00/06698	10.02.00	PCT			
	8	WO 00/12708	09.03.00	PCT			
	9	WO 00/52151	08.09.00	PCT			
	10	WO 00/60076	12.10.00	PCT			
	11	WO 00/71581 A1	30.11.00	PCT			
	12	WO 00/73346 A1	07.12.00	PCT			
	13	WO 00/78960 A2	28.12.00	PCT			
	14	WO 00/78961 A1	28.12.00	PCT			
	15	WO 01/16318 A2	08.03.01	PCT			
	16	WO 01/53455 A2	26.07.01	PCT			
	17	WO 01/62891 A2	30.08.01	PCT			
	18	WO 01/68848 A2	20.09.01	PCT			
	19	WO 02/00690 A2	03.01.02	PCT			
	20	WO 02/071928 A2	19.09.02	PCT			
	21	WO 02/08284 A2	31.01.02	PCT			
	22	WO 02/16602 A2	28.02.02	PCT			
	23	WO 02/42487 A2	30.05.02	PCT			
	24	WO 92/09690	11.06.92	PCT			
	25	WO 98/54963	10.12.98	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	26	Holt et al., "Domain antibodies: proteins for therapy" <u>Trends Biotechnol.</u> 21(11):484-490 (Nov 2003)
	27	Pyagay et al., "Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration" <u>Circ Res.</u> (online: December 23, 2004) 96(2):261-268

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.